Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAC-PRO: Macitentan in Acute Pulmonary Embolism
NCT05946811Phase 3Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary embolism (PE) comparing Macitentan arm with Placebo arm (2 arms). Primary endpoint: Percentage of pulmonary artery occlusion (Residual pulmonary vascular occlusion) at 3 months. Planned start May 2024; status: withdrawn.
02
Drugs
macitentan
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT05946811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946811.